Cambrex, a global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services, has entered into a definitive agreement to acquire Snapdragon Chemistry, a U.S.-based provider of chemical process development services to a broad range of emerging and established biopharma customers.
 
Snapdragon specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, using state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges. The team of scientists and engineers apply deep process understanding afforded by data-rich experimentation to design and rapidly execute efficient GMP and non-GMP manufacturing processes. Snapdragon has 74 employees with R&D and manufacturing headquartered in Waltham, MA.
 
Snapdragon recently opened its second facility, a new 51,000-sq.-ft. facility to manufacture experimental pharmaceutical products for clinical trials, expanding capacity to supply clinical intermediates and drug substances.

“The acquisition of Snapdragon will accelerate our growth in the area of continuous flow process development and manufacturing, complementing our recent organic investments in our High Point, North Carolina facility,” said Tom Loewald, CEO of Cambrex. “With R&D and manufacturing capabilities in the heart of Boston’s biopharma hub, Snapdragon will continue to focus on solving their customers’ most difficult process development challenges.”
 
“We are excited to be joining Cambrex, a company with over 40 years of drug substance development and manufacturing expertise,” said Matt Bio, CEO of Snapdragon. “Partnering our best-in-class process development capabilities with Cambrex’s larger scale manufacturing facilities in North America and Europe is a natural fit, both for our employees and our customers.”
 
This will be Cambrex’s second acquisition within a year along with Q1 Scientific and is part of the company’s strategy to expand its portfolio of specialized services for pharmaceutical development and manufacturing.